AUTHORS
Meiyin Lin, PhD, Siddhant Kadu2, Jordan Reff3, Linhui Chen4, Carl H. June Jr, MD5, Neil Sheppard, PhD6
AFFILIATIONS
1 University of Pennsylvania, Philadelphia, Pennsylvania, United States
2 University of Pennsylvania, Philadelphia, Pennsylvania, United States
3 University of Pennsylvania, Philadelphia, Pennsylvania, United States
4 University of Pennsylvania, Philadelphia, Pennsylvania, United States
5 University of Pennsylvania, Philadelphia, Pennsylvania, United States
6 University of Pennsylvania, Philadelphia, Pennsylvania, United States
ABSTRACT
Background
Natural killer (NK) cells are attractive "off-the-shelf" allogeneic adoptive cell therapies because they mediate antigen-independent tumor killing and do not induce graft-versus-host disease (GVHD). However, clinical responses to NK-cell therapy have been modest. Tacrolimus is a potent T cell immunosuppressant that inhibits the Ca²⁺-calcineurin–nuclear factor of activated T cells (NFAT) signaling pathway. Unexpectedly, tacrolimus enhances NK-effector functions. Here, we evaluated the feasibility of using tacrolimus-exposed NK cells (Tac-NK) as an adoptive cellular therapy and investigated the mechanisms underlying this paradoxical effect.
Methods
NK cells were expanded for 10 days using irradiated K562 feeder cells expressing membrane-bound IL-21, 4-1BBL, CD64, and CD40, followed by exposure to tacrolimus for an additional 5 days. Cells were harvested and washed on day 15. Cytotoxicity was evaluated against multiple tumor cell lines, including AsPC1 (pancreatic adenocarcinoma), MM.1S (multiple myeloma), Raji (Burkitt lymphoma), and U251 (glioblastoma), in both two-dimensional and three-dimensional spheroid culture systems. Antibody-dependent cellular cytotoxicity (ADCC) was assessed against JeKo-1 (mantle cell lymphoma) and SKOV3 (ovarian cancer) cells in the presence of rituximab (anti-CD20) and trastuzumab (anti-HER2), respectively.
For in vivo studies, NOD/scid/IL2rγ−/− (NSG) mice were orthotopically engrafted with AsPC1 or Raji cells prior to Tac-NK cell administration. Metabolic profiling was performed using Seahorse assays, and bulk RNA sequencing was conducted on day 11 and day 15 NK cells to identify transcriptional changes associated with tacrolimus exposure.
Results
Tac-NK cells demonstrated reduced proliferation but consistently enhanced cytotoxicity across multiple tumor cell lines, demonstrating a two- to nine-fold lower half-maximal effective dose (EC50) than vehicle (DMSO)-control NK (Veh-NK) cells. Notably, Tac-NK cells in the absence of therapeutic monoclonal antibodies (mAbs) achieved cytotoxicity comparable to that of Veh-NK with such antibodies, while addition of mAbs further enhanced Tac-NK cells activity, to approximately three-fold lower EC50 than mAb-treated Veh-NK cells, thus demonstrating enhanced natural cytotoxicity and ADCC. Enhanced antitumor activity was also observed in vivo, where Tac-NK cells reduced tumor burden and prolonged survival. Mechanistic studies identified that the activating receptor NKG2D contributed substantially to the enhanced cytotoxicity.
Metabolic studies by Seahorse XF analyzer revealed increased glycolytic activity in Tac-NK cells. Pharmacologic inhibition of glycolysis with 2-deoxy-D-glucose abrogated the enhanced cytotoxicity, indicating that metabolic reprogramming directly contributes to their improved effector function. Consistent with these findings, Tac-NK cells also exhibited increased surface expression of glucose transporter GLUT1.
Bulk RNA sequencing identified Nuclear Receptor Subfamily 4 Group A Member 2 (NR4A2) as one of the most significantly downregulated genes following tacrolimus treatment. Consistent with this finding, pharmacologic inhibition of NR4A2 using a reverse agonist enhanced NK-cell cytotoxicity, suggesting that NR4A2 functions as a negative regulator of NK-cell effector function.
Conclusions
Tacrolimus paradoxically enhances NK-cell antitumor activity through metabolic reprogramming and downregulation of NR4A2. These findings identify a previously unrecognized mechanism regulating NK-cell function and support the development of Tac-NK cells as a broadly applicable adoptive cellular immunotherapy for cancer.
DISCLOSURES
Meiyin Lin, PhD: No relevant conflicts of interest to declare.